Literature DB >> 9223579

Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation.

L K Ludden1, T M Ludden, J M Collins, H S Pentikis, J M Strong.   

Abstract

The effect of bovine serum albumin (BSA) on human liver metabolism, in vitro, of 14C-phenytoin (PHT) was studied. Michaelis Menten parameters were determined for the conversion of PHT to p-hydroxy phenytoin in seven different microsomal preparations with the addition of 0, 2, and 4% BSA. The unbound Km (Kmu) values were 30.8 +/- 18.6, 1.57 +/- 0.21 and 1.50 +/- 0.17 microM (mean +/- S.D.), respectively; however, there was excellent agreement among the Vmax values (29.1, 31.8 and 31.5 pmol/min/mg). With intact tissue slices, BSA (4%) added to incubations of PHT had a minimal effect on the Vmax values in two of the four livers studied and resulted in a mean Kmu value of 2.20 +/- 0.59 microM, although the Kmu in the absence of BSA was 6.64 +/- 3.17. In scaling-up to the whole body, Vmax values were 3.9 and 1.0 mg/kg/day for microsomes and slices, respectively, compared to 5.9 mg/kg/day, in vivo. The Kmu values determined in the presence of albumin in both microsomes and slices were similar to those based on in vivo human steady state data (Kmu = 2-3 microM), and the intersubject variation, in vitro, was decreased in the presence of BSA. These findings for phenytoin metabolism suggest that the addition of albumin to incubation media for slices or microsome experiments may yield Km estimates that are more representative of in vivo values.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223579

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

2.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

3.  Nonspecific binding of drugs to human liver microsomes.

Authors:  J A McLure; J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 4.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.

Authors:  Nitsupa Wattanachai; Thomas M Polasek; Tahlia M Heath; Verawan Uchaipichat; Wongwiwat Tassaneeyakul; Wichittra Tassaneeyakul; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2011-02-09       Impact factor: 2.953

6.  Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.

Authors:  Verawan Uchaipichat; Leanne K Winner; Peter I Mackenzie; David J Elliot; J Andrew Williams; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

7.  Assessment of inter-individual variability in predicted phenytoin clearance.

Authors:  Thomas M Polasek; Sebastian Polak; Matthew P Doogue; Amin Rostami-Hodjegan; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

8.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

Review 9.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Authors:  A Hsu; G R Granneman; R J Bertz
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

10.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.